Nexien Biopharma Inc
Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions in the United States. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in … Read more
Nexien Biopharma Inc (NXEN) - Total Liabilities
Latest total liabilities as of March 2025: $458.80K USD
Based on the latest financial reports, Nexien Biopharma Inc (NXEN) has total liabilities worth $458.80K USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nexien Biopharma Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Nexien Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nexien Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Nexien Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mobile Streams Plc
LSE:MOS
|
UK | GBX538.00K |
|
Oppmann Immobilien AG
MU:SOP
|
Germany | €1.95 Million |
|
ORCO GERMANY - Dusseldorf Stock Exchang
DU:O5G
|
Germany | €12.80 Billion |
|
Blackstone / GSO Loan
LSE:BGLF
|
UK | €3.08 Million |
|
SFD
WAR:SFD
|
Poland | zł85.44 Million |
|
OUE (OUE1.SG)
STU:OUE1
|
Germany | €3.39 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Nexien Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 55.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nexien Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nexien Biopharma Inc (2015–2024)
The table below shows the annual total liabilities of Nexien Biopharma Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | $365.43K | +23.82% |
| 2023-06-30 | $295.13K | +21.89% |
| 2022-06-30 | $242.12K | +515.84% |
| 2021-06-30 | $39.32K | +34.87% |
| 2020-06-30 | $29.15K | -34.86% |
| 2019-06-30 | $44.75K | -49.60% |
| 2018-06-30 | $88.78K | -57.80% |
| 2017-06-30 | $210.41K | +201.00% |
| 2016-06-30 | $69.90K | +42.91% |
| 2015-06-30 | $48.91K | -- |